Genmab A/S (NASDAQ:GMAB) PT rose to $33.00 on SVB Leerink

Genmab A/S (NASDAQ:GMAB) PT rose to .00 on SVB Leerink

Genmab A/S (NASDAQ:GMABget rating) SVB Leerink stock researchers raised their price target from $31.00 to $33.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “market performance” rating on the stock. SVB Leerink’s price target suggests a possible drop of 20.06% from the company’s current price.

Other stock analysts also recently issued research reports on the company. DNB Markets downgraded Genmab A/S from a “buy” rating to a “hold” rating in a report dated Monday, Oct. 17. HC Wainwright raised its price target on Genmab A/S from $49.00 to $51.00 and gave the company a “buy” rating in a report on Monday, August 22. Morgan Stanley raised its price target on Genmab A/S from $29.00 to $31.00 and gave the company an “underweight” rating in a report on Monday, August 15. Finally, TheStreet upgraded Genmab A/S from a “c+” rating to a “b” rating in a research report on Wednesday, August 31. One stock research analyst rated the shares a sell rating, eight assigned a hold rating and two assigned a buy rating to the company’s shares. According to MarketBeat data, the stock has a consensus rating of “Hold” and an average price target of $547.96.

Shares of Genmab A/S increased by 3.1%

Actions of Shares of Genmab A/S opened at $41.28 on Thursday. The company has a market cap of $27.17 billion, a PE ratio of 45.87, a P/E/E ratio of 1.48, and a beta of 0.94. The company has a 50-day moving average of $36.27 and a 200-day moving average of $34.08. Genmab A/S has a 52-week minimum of $26.19 and a 52-week maximum of $43.98.

Genmab A/S (NASDAQ:GMABget rating) last announced its earnings results on Wednesday, August 10. The company reported $0.41 EPS for the quarter, beating analyst consensus estimates of $0.21 by $0.20. The company had revenue of $452.86 million during the quarter, compared to the consensus estimate of $435.40 million. Genmab A/S had a return on equity of 17.12% and a net margin of 38.42%. On average, research analysts anticipate Genmab A/S to post 1.01 earnings per share for the current year.

Institutional investors weigh in on Genmab A/S

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its holding in shares of Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company valued at $198,799,000 after buying an additional 86,571 shares last quarter. Capital International Investors increased its shareholding in Genmab A/S by 7.7% during the first quarter. Capital International Investors now owns 3,952,446 shares of the company valued at $145,433,000 after purchasing an additional 283,031 shares during the last quarter. Wellington Management Group LLP increased its shareholding in Genmab A/S by 5.8% during the first quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company valued at $120,618,000 after purchasing an additional 183,578 shares during the last quarter. Renaissance Technologies LLC increased its shareholding in Genmab A/S by 1.3% during the first quarter. Renaissance Technologies LLC now owns 1,088,500 shares of the company valued at $39,382,000 after purchasing an additional 14,100 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its shareholding in Genmab A/S by 63.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 869,221 shares of the company valued at $31,448,000 after purchasing an additional 338,902 shares during the last quarter. Hedge funds and other institutional investors own 5.51% of the company’s shares.

About Genmab A/S

(get rating)

Genmab A/S develops antibody therapies for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured articles

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

This instant news alert was powered by MarketBeat’s financial data and narrative science technology to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Genmab A/S, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five actions that major analysts quietly whisper to their clients to buy now before the broader market realizes it… and Genmab A/S was not on the list.

While Genmab A/S currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Leave a Comment